KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

医学 来那度胺 内科学 多发性骨髓瘤 肿瘤科 临床终点 氟达拉滨 自体干细胞移植 环磷酰胺 移植 队列 临床研究阶段 临床试验 外科 化疗
作者
Saad Z. Usmani,Krina K. Patel,Parameswaran Hari,Jesús G. Berdeja,Melissa Alsina,Ravi Vij,Noopur Raje,Xavier Leleu,Madhav V. Dhodapkar,Ran Reshef,Anna Truppel-Hartmann,Debashree Basudhar,Ethan Thompson,Xirong Zheng,Revathi Ananthakrishnan,Chiara Greggio,Linda Favre-Kontula,Lars Sternas,Jesús F. San Miguel
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 875-877 被引量:37
标识
DOI:10.1182/blood-2022-162469
摘要

**Co-lead author Introduction Patients with multiple myeloma (MM) who relapse early after frontline therapy with autologous stem cell transplant (ASCT) have a poor prognosis. Novel therapies are needed to improve outcomes (Paiva Blood 2012; Bygrave Br J Haematol 2020). In the pivotal phase 2 KarMMa study (NCT03361748), treatment with the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy idecabtagene vicleucel (ide-cel) resulted in frequent, deep, and durable responses in pts with relapsed and refractory MM (RRMM) who were triple-class exposed and refractory to last treatment (Munshi N Engl J Med 2021). KarMMa-2 is a multicohort, phase 2, multicenter trial (NCT03601078) of ide-cel in RRMM and in clinical high-risk MM, defined as early relapse after frontline therapy (cohorts 2a, 2b) or inadequate response after frontline ASCT (2c). The efficacy and safety of ide-cel in cohort 2a are presented. Methods Eligible pts in cohort 2a had early relapse after frontline therapy, defined as progressive disease (PD) <18 mo from starting treatment containing induction, ASCT (single or tandem), and lenalidomide-containing maintenance. After lymphodepletion (cyclophosphamide 300 mg/m2 + fludarabine 30 mg/m2 × 3), pts received a single infusion of ide-cel at 150-450 × 106 CAR+ T cells. The primary efficacy endpoint was complete response (CR) rate (CRR; CR and stringent CR) by investigator per IMWG criteria. Secondary endpoints included overall response rate (ORR; ≥ partial response), time to response (TTR), duration of response (DOR), PFS, OS, safety, and pharmacokinetics (PK). Exploratory endpoints included assessment of soluble BCMA (sBCMA) level and minimal residual disease negativity (MRD-) by next-generation sequencing (<10-5 nucleated cells). Efficacy and safety were analyzed in all pts who received ide-cel; PK and sBCMA were analyzed in evaluable pts. MRD- is reported for evaluable pts with ≥CR. Results Ide-cel was successfully manufactured and infused in 37/39 pts. Median age was 57 y; median time since diagnosis was 1.6 y. A total of 62.2% pts had ECOG PS 0, and 70.3% received bridging therapies (corticosteroids, alkylating agents, immunomodulatory agents, proteasome inhibitors [PI], and/or anti-CD38 antibodies) for MM. At study entry, 13.5%/51.4%/5.4% pts had R-ISS stage I/II/III disease, 32.4% had high-risk cytogenetics, 18.9% had bone marrow biopsy-determined high tumor burden (≥50% bone marrow CD138+ plasma cells), and 8.1% had extramedullary disease. Most pts had disease refractory to an immunomodulatory agent (86.5%) or PI (89.2%); 86.5% had double refractory disease. At data cut-off (14 Mar 2022), median follow-up was 21.5 mo (range 2-31). CRR was 45.9% (95% CI 29.5-63.1), and ORR was 83.8% (95% CI 68.0-93.8) (Table 1). At 6 mo post-ide-cel, MRD− was observed in 11/13 (85%; 95% CI 57.8-95.7) pts. At 12 mo, MRD− was observed in 7/10 (70%; 95% CI 39.7-89.2) pts; of the 7 pts, 1 had PD at 20.8 mo, 5 sustained MRD− at ≥18 mo, and >12 mo data was unavailable for 1 pt. Median TTR was 1 mo (range 0.9-2.9). Median DOR was 15.7 mo (95% CI 7.62-19.81). Median PFS was 11.4 mo (95% CI 5.55-19.58); median OS was not reached. Time to event endpoint results for DOR, PFS, and OS are shown in Table 1. Grade (Gr) 3-4 AEs on or after ide-cel infusion occurred in all pts, most commonly neutropenia in 35 (94.6%) pts, anemia in 17 (45.9%), and thrombocytopenia in 14 (37.8%). Two pts died due to pneumonia and pseudomonal sepsis. Gr 1/2 cytokine release syndrome (CRS) occurred in 30 (81.1%) pts; 1 (2.7%) pt had a Gr 3 event (Table 1). Gr 1/2 investigator-identified neurotoxicity (NT) occurred in 8 (21.6%) pts; no pts had ≥Gr 3 NT. Robust cell expansion was seen in 36 evaluable pts (Table 2). Ide-cel cellular expansion levels were higher in pts who had ≥CR vs those who had 18 mo. The incidence of CRS and NT were similar in these pts vs those treated with ide-cel in later lines. These results support a favorable clinical benefit-risk profile of ide-cel and its potential use in earlier lines of treatment. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tianny关注了科研通微信公众号
1秒前
1秒前
CO2发布了新的文献求助10
1秒前
桐桐应助zhangscience采纳,获得10
2秒前
求助发布了新的文献求助10
3秒前
buno应助zoe采纳,获得10
4秒前
junzilan发布了新的文献求助10
4秒前
4秒前
细品岁月完成签到 ,获得积分10
4秒前
细心书蕾完成签到 ,获得积分10
5秒前
无花果应助l11x29采纳,获得10
7秒前
7秒前
老詹头发布了新的文献求助10
7秒前
思源应助叫滚滚采纳,获得10
8秒前
9秒前
刘歌完成签到 ,获得积分10
9秒前
阿巡完成签到,获得积分10
9秒前
Chen完成签到,获得积分10
11秒前
LSH970829发布了新的文献求助10
11秒前
哈哈哈完成签到 ,获得积分10
12秒前
汤姆完成签到,获得积分10
12秒前
14秒前
14秒前
翠翠完成签到,获得积分10
15秒前
15秒前
LSH970829完成签到,获得积分10
16秒前
Lyg完成签到,获得积分20
17秒前
坚强的樱发布了新的文献求助10
17秒前
baodingning完成签到,获得积分10
18秒前
18秒前
公茂源发布了新的文献求助30
18秒前
热爱完成签到,获得积分10
19秒前
20秒前
叫滚滚发布了新的文献求助10
21秒前
星瑆心完成签到,获得积分10
21秒前
啦啦啦啦啦完成签到,获得积分10
22秒前
Lyg发布了新的文献求助10
22秒前
Dksido完成签到,获得积分10
23秒前
兰博基尼奥完成签到,获得积分10
23秒前
热情芷荷发布了新的文献求助10
25秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527961
求助须知:如何正确求助?哪些是违规求助? 3108159
关于积分的说明 9287825
捐赠科研通 2805882
什么是DOI,文献DOI怎么找? 1540070
邀请新用户注册赠送积分活动 716926
科研通“疑难数据库(出版商)”最低求助积分说明 709808